Calcium channel blockers (versus unexposed)

Preeclampsia

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13387
R52256		 Mito - Amlodipine, 2019 Superimposed preeclampsia at least 1st trimester retrospective cohort unexposed, sick Adjustment: No Indications Antihypertensive: Only chronic hypertension indication 0.91 [0.45;1.85] C 15/48   43/129 58 48
ref
S13789
R54075		 Bayliss - Calcium blockers, 2002 Superimposed Pre-eclampsia (before and after 30 weeks) throughout pregnancy retrospective cohort unexposed, sick Adjustment: No Indications Antihypertensive: Only chronic hypertension indication 0.49 [0.13;1.83] C 3/14   61/171 64 14
ref
Total 2 studies 0.79 [0.42;1.48] 122 62
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Mito - Amlodipine, 2019Mito - Amlodipine, 2019 0.91[0.45; 1.85]584877%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Bayliss - Calcium blockers, 2002Bayliss - Calcium blockers, 2002 0.49[0.13; 1.83]641423%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 0.79[0.42; 1.48]122620.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.79[0.42; 1.48]122620%NAMito - Amlodipine, 2019 Bayliss - Calcium blockers, 2002 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.79[0.42; 1.48]122620%NAMito - Amlodipine, 2019 Bayliss - Calcium blockers, 2002 2 Tags Adjustment   - No  - No 0.79[0.42; 1.48]122620%NAMito - Amlodipine, 2019 Bayliss - Calcium blockers, 2002 2 Indications Antihypertensive   - Only chronic hypertension indication  - Only chronic hypertension indication 0.79[0.42; 1.48]122620%NAMito - Amlodipine, 2019 Bayliss - Calcium blockers, 2002 2 All studiesAll studies 0.79[0.42; 1.48]122620%NAMito - Amlodipine, 2019 Bayliss - Calcium blockers, 2002 20.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 0.79[0.42; 1.48]122620%NAMito - Amlodipine, 2019 Bayliss - Calcium blockers, 2002 20.510.01.0

Umbrella review (other published meta-analyses)

Published MATE95% CIn exposedkI2Control groupExposition period AbalosAbalos 1.40[1.02; 1.92]16%-unexposed, sickduring pregnancy (anytime or not specified)studies4 Bellos - AmlodipineBellos - Amlodipine 0.70[0.09; 5.45]NA-unexposed, sickduring pregnancy (anytime or not specified)studies-9 Bellos - AmlodipineBellos - Amlodipine 0.84[0.30; 2.33]NA-unexposed, sickduring pregnancy (anytime or not specified)studies-9 Bellos - NifedipineBellos - Nifedipine 0.66[0.20; 2.16]NA-unexposed, sickduring pregnancy (anytime or not specified)studies-9 Bellos - NifedipineBellos - Nifedipine 0.82[0.34; 3.88]NA-unexposed, sickduring pregnancy (anytime or not specified)studies-9 Bone - GESTATIONAL HYPERTENSIONBone - GESTATIONAL HYPERTENSION 0.77[0.49; 1.19]23%-unexposed, sickduring pregnancy (anytime or not specified)studies-9 Bone - GESTATIONAL HYPERTENSIONBone - GESTATIONAL HYPERTENSION Out of scale0.11[0.01; 0.99]32%-exposed to other treatment, sickduring pregnancy (anytime or not specified)studies-9 metaPregmetaPreg 0.79[0.42; 1.48]0%62--Mito - Amlodipine, 2019 Bayliss - Calcium blockers, 2002 20.510.01.0